IVA NASDAQ
Credit Risk of going bust: higher than 81% of companies Debt: 27.9% of company value Bonds: none of note held by US funds details ▾
Total debt $74.2M against a stock market value of $191.6M.
Distance to default 2.50 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $44.5M (short-term plus half of long-term), stock volatility 74.3%; Altman Z'' 1.03. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Daix, BF 21121
FR
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
